Aims Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart
failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and …

Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly
reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Background: Goals of management in patients with heart failure and reduced ejection
fraction include reducing death and hospitalizations, and improving health status …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Background Patients with heart failure (HF) have a high burden of multimorbidity, often
necessitating numerous medications. There may be clinical concern about introducing …

Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …